AURA Stock Price, Aura Biosciences, Inc. Quote, Chart

Market Summary

USD7.25+0.05

Delayed

0.69%

AURA Stock Price

View Fullscreen

AURA RSI Chart

AURA Valuation

Market Cap

359.2M

Price/Earnings (Trailing)

-4.57

EV/EBITDA

-4.44

Price/Free Cashflow

-4.95

MarketCap/EBT

-4.71

AURA Price/Earnings (Trailing)

AURA Profitability

Return on Equity

-37.67%

Return on Assets

-33.46%

Free Cashflow Yield

-20.21%

AURA Fundamentals

AURA Earnings

Earnings (TTM)

-78.6M

Earnings Growth (Yr)

-12.82%

Earnings Growth (Qtr)

10.96%

Breaking Down AURA Revenue

Last 7 days

-0.8%

Last 30 days

3.1%

Last 90 days

-18.0%

Trailing 12 Months

-39.0%

How does AURA drawdown profile look like?

AURA Financial Health

Current Ratio

21.97

AURA Investor Care

Shares Dilution (1Y)

31.07%

Diluted EPS (TTM)

-1.87

Tracking the Latest Insider Buys and Sells of Aura Biosciences, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 02, 2024	kilroy conor	acquired	-	-	96,000	general counsel and secretary
Feb 01, 2024	feder julie b	acquired	-	-	71,285	chief financial officer
Feb 01, 2024	de los pinos elisabet	acquired	-	-	162,935	see remarks
Feb 01, 2024	hopkins janet jill	acquired	-	-	28,515	chief medical officer
Jan 23, 2024	de los pinos elisabet	sold	-121,141	7.6415	-15,853	see remarks
Jan 23, 2024	feder julie b	sold	-50,521	7.6443	-6,609	chief financial officer
Nov 09, 2023	matrix capital management company, lp	bought	14,040,000	9.00	1,560,000	-
Nov 08, 2023	johnson david michael	bought	73,000	7.3	10,000	-
Nov 08, 2023	johnson david michael	bought	70,087	7.3	9,601	-

Which funds bought or sold AURA recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	reduced	-26.97	-90,029	165,023	-%
May 16, 2024	LEVIN CAPITAL STRATEGIES, L.P.	added	11.2	-13,080	872,920	0.09%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-21.49	-12,323	28,158	-%
May 15, 2024	PRICE T ROWE ASSOCIATES INC /MD/	reduced	-9.72	-1,169,000	4,676,000	-%
May 15, 2024	OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC)	reduced	-25.19	-268,899	528,501	0.04%
May 15, 2024	ADAGE CAPITAL PARTNERS GP, L.L.C.	added	5.68	-2,383,250	35,050,200	0.07%
May 15, 2024	TWO SIGMA INVESTMENTS, LP	added	168	518,480	894,029	-%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	new	-	555,128	555,128	-%
May 15, 2024	MARSHALL WACE, LLP	new	-	292,083	292,083	-%
May 15, 2024	Hudson Bay Capital Management LP	sold off	-100	-470,218	-	-%

Are Funds Buying or Selling AURA?

Are funds buying AURA calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own AURA

No. of Funds

Unveiling Aura Biosciences, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	citadel advisors llc	7.2%	6	SC 13G/A
Feb 07, 2024	adage capital partners gp, l.l.c.	8.61%	4,225,000	SC 13G/A
Dec 11, 2023	eventide asset management, llc	11.82%	5,802,682	SC 13G/A
Nov 09, 2023	matrix capital management company, lp	14.10%	6,922,870	SC 13D/A
Feb 14, 2023	citadel advisors llc	7.4%	6	SC 13G/A
Feb 14, 2023	eventide asset management, llc	6.3%	2,251,368	SC 13G
Feb 10, 2023	arix bioscience plc	4.1%	1,508,483	SC 13G/A
Feb 09, 2023	adage capital partners gp, l.l.c.	5.76%	2,132,739	SC 13G/A
Jan 20, 2023	chiesi ventures, inc.	3.3%	1,218,803	SC 13G/A
Dec 15, 2022	adage capital partners gp, l.l.c.	5.65%	2,090,665	SC 13G

Recent SEC filings of Aura Biosciences, Inc.

View All Filings

Date Filed	Form Type	Document
May 09, 2024	10-Q	Quarterly Report
May 09, 2024	8-K	Current Report
Apr 25, 2024	ARS	ARS
Apr 25, 2024	DEF 14A	DEF 14A
Apr 25, 2024	DEFA14A	DEFA14A
Apr 15, 2024	8-K	Current Report
Apr 15, 2024	PRE 14A	PRE 14A
Apr 05, 2024	EFFECT	EFFECT
Apr 04, 2024	4	Insider Trading
Apr 04, 2024	3	Insider Trading

Peers (Alternatives to Aura Biosciences, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Aura Biosciences, Inc. News

Latest updates

Aura Biosciences, Inc. Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet												(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2020Q4
Assets	-7.9%	235	255	180	193	206	224	143	135	146	160	91.00	22.00
Current Assets	-8.4%	212	232	154	166	179	197	116	128	140	154	83.00	18.00
Cash Equivalents	-36.0%	26.00	41.00	56.00	48.00	38.00	122	61.00	54.00	108	149	82.00	17.00
Net PPE	-3.0%	3.00	3.00	5.00	5.00	5.00	5.00	5.00	6.00	6.00	5.00	4.00	4.00
Liabilities	-10.2%	26.00	29.00	28.00	26.00	26.00	28.00	28.00	6.00	5.00	8.00	6.00	3.00
Current Liabilities	-21.8%	10.00	12.00	11.00	9.00	8.00	10.00	10.00	6.00	5.00	7.00	6.00	3.00
Shareholder's Equity	-7.6%	209	226	152	166	180	196	115	129	141	152	-	-
Retained Earnings	-6.9%	-307	-287	-265	-246	-228	-210	-194	-178	-164	-152	-140	-116
Additional Paid-In Capital	0.6%	516	513	417	413	409	407	310	308	306	304	9.00	8.00
Shares Outstanding	0.3%	50.00	49.00	38.00	38.00	38.00	38.00	29.00	29.00	29.00	29.00	-	0.00
Float	-	-	-	-	225	-	-	-	280	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)															(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3
Cashflow From Operations	-40.6%	-24,452	-17,387	-15,403	-14,645	-16,412	-18,013	-10,760	-10,628	-15,200	-12,086	-8,690	-6,497	-5,137	-	-
Share Based Compensation	11.8%	2,909	2,603	2,325	1,931	1,913	1,814	1,717	1,287	1,594	1,297	554	271	185	-	-
Cashflow From Investing	110.4%	9,396	-90,120	21,629	21,407	-66,879	-16,876	17,946	-43,441	-25,498	-819	-573	-662	-71.00	-	-
Cashflow From Financing	-99.7%	253	92,985	1,626	2,478	201	95,199	104	309	17.00	80,142	-1,116	-256	87,489	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

AURA Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating Expenses:
Research and development	$ 17,052	$ 14,405
General and administrative	5,261	5,039
Total operating expenses	22,313	19,444
Total operating loss	(22,313)	(19,444)
Other income (expense):
Interest income, including amortization and accretion income	2,685	1,991
Other income (expense)	(32)	(13)
Total other income	2,653	1,978
Loss before income taxes	(19,660)	(17,466)
Income tax benefit (provision),net	(46)	0
Net loss	$ (19,706)	$ (17,466)
Net loss per common share - basic	$ (0.4)	$ (0.46)
Net loss per common share - diluted	$ (0.4)	$ (0.46)
Weighted average common stock outstanding - basic	49,451,943	37,784,282
Weighted average common stock outstanding - diluted	49,451,943	37,784,282
Comprehensive loss:
Net loss	$ (19,706)	$ (17,466)
Other comprehensive items:
Unrealized gain (loss) on marketable securities	(521)	27
Total other comprehensive income (loss)	(521)	27
Total comprehensive loss	$ (20,227)	$ (17,439)

AURA Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 26,279	$ 41,063
Marketable securities	176,595	185,087
Restricted cash and deposits	0	19
Prepaid expenses and other current assets	9,375	5,625
Total current assets	212,249	231,794
Restricted cash and deposits, net of current portion	768	768
Right of use assets - operating lease	18,501	18,854
Other long-term assets	453	509
Property and equipment, net	3,054	3,150
Total Assets	235,025	255,075
Current liabilities:
Accounts payable	1,933	1,787
Short-term operating lease liability	2,741	2,687
Accrued expenses and other current liabilities	4,989	7,883
Total current liabilities	9,663	12,357
Long-term operating lease liability	16,579	16,870
Total Liabilities	26,242	29,227
Commitments and Contingencies (Note 12)
Stockholders Equity:
Common stock, $0.00001 par value, 150,000,000 authorized at March 31, 2024 and December 31, 2023, and 49,504,405 and 49,350,788 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively
Additional paid-in capital	515,779	512,617
Accumulated deficit	(307,014)	(287,308)
Accumulated other comprehensive loss	18	539
Total Stockholders' Equity	208,783	225,848
Total Liabilities and Stockholders Equity	$ 235,025	$ 255,075

About Aura Biosciences, Inc.

Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for treating tumors of high unmet need in ocular and urologic oncology. It is developing AU-011, a VDC candidate for the treatment of primary choroidal melanoma that is in phase III clinical trial. The company also develops AU-011 for additional ocular oncology indications, including choroidal metastases and is in Phase 2 dose-escalation trial. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.

CEO	Dr. Elisabet de los Pinos Ph.D.
WEBSITE	aurabiosciences.com
INDUSTRY	Biotechnology
EMPLOYEES	70

Aura Biosciences, Inc. Frequently Asked Questions

What is the ticker symbol for Aura Biosciences, Inc.? What does AURA stand for in stocks?

AURA is the stock ticker symbol of Aura Biosciences, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Aura Biosciences, Inc. (AURA)?

As of Fri May 17 2024, market cap of Aura Biosciences, Inc. is 359.19 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AURA stock?

You can check AURA's fair value in chart for subscribers.

What is the fair value of AURA stock?

You can check AURA's fair value in chart for subscribers. The fair value of Aura Biosciences, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Aura Biosciences, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AURA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Aura Biosciences, Inc. a good stock to buy?

The fair value guage provides a quick view whether AURA is over valued or under valued. Whether Aura Biosciences, Inc. is cheap or expensive depends on the assumptions which impact Aura Biosciences, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AURA.